Etiological evaluation of the elevated transaminases in children

Transaminaz yüksekliği olan çocuklarda etyolojik değerlendirilmeye

Aslıhan Sanrı¹, Ceyda Tuna Kırsaçıoğlu², Emre Sanrı¹, Tülin Revide Şaylı¹³

¹Department of Pediatrics, ²Department of Pediatric Gastroenterology, ³Department of Pediatrics Hematology, Turkish Republic Health Ministry, Ankara Child Health Diseases, Haematology Oncology Training and Research Hospital, Ankara, Turkey.

Corresponding author: Aslıhan Sanrı, MD, Turkish Republic Health Ministry, Ankara Child Health Diseases, Haematology Oncology Training and Research Hospital, Ankara, Turkey
E-mail: asilhanaltunoglu@gmail.com
Received/Accepted: July 17, 2019 / April 29, 2020
Conflict of interest: There is not a conflict of interest.

SUMMARY

Objective: We aimed to determine the etiology of hypertransaminasemia in children, demonstrate the differences according to the age and evaluate course of transaminases.

Method: We retrospectively analyzed the medical records of children who presented with elevated transaminase levels for at least 2 months, aged between 3 months and 18 years, for demographic features, laboratory, radiologic and histopathological findings.

Results: Among total 292 children, 194 (66.4%) were male and 98 (33.6%) were female. The mean age was 6.5±5.4 years. The 45.9% of the children had no complaints at presentation. Majority of the patients had mildly elevated transaminases (81.6%). The most common etiology was non-alcoholic fatty liver disease (NAFLD) (25.7%). The NAFLD was more prevalent in patients older than 5 years-old (p<0.001). The second cause was infectious diseases (97.8% were viral infections) and more prevalent in patients younger than 2 years-old (p=0.043). In 34.1% of the children, no overt cause of hypertransaminasemia was identified. The patients with unidentified etiology were significantly younger, but had higher mean aspartate aminotransferase (AST) levels than the patients in whom the etiology was identified (p= <0.0001, p=0.008 respectively). The normalization of transaminases was seen in 40.4% of the patients at mean 5.4±4.4 months. The shortest normalization time was observed in drug related liver injury (DILI) among all other etiologies (p=0.015).

Conclusions: The most common cause of hypertransaminasemia in childhood were NAFLD and viral infections, which varies by age. A stepwise approachment to hypertransaminasemia leads to early diagnosis.

Keywords: Hypertransaminasemia, children, infectious diseases, obesity.

ÖZET

Amaç: Çocuklarda transaminaz yüksekliğinin etiolojisini belirlemeyi, yaşa göre farklılıkları göstermeyi ve transaminazların seyrini değerlendirmeyi amaçladık.

Yöntem: En az 2 aydır devam eden transaminaz yüksekliği olan, 3 ay ile 18 yaş arasında çocukların tıbbi kayıtları demografik özellikleri, laboratuvar, radyolojik ve histopatolojik bulgular açısından geriye dönük olarak inceledi.

Bulgular: 292 çocuğun 194’ü (%66.4) erkek ve 98’i (%33.6) kızdı. Yaş ortalaması 6,5 ± 5,4 yıl idi. Çocukların % 45.9’unun başvurdu sırasında herhangi bir aktif şikayet yoktu. Hastaların % 81.6’sında transaminaz yüksekliği hafifti. En
INTRODUCTION

The measurement of serum transaminase levels as a part of the routine biochemical evaluation before surgery or for the investigation of any other conditions, lead to increase the incidental determination of hypertransaminasemia in childhood. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are not liver-specific enzymes. So, the elevation of transaminases are not always related to liver disease, but also any other condition such as muscle diseases, genetic/metabolic disorders etc.

There are only a few reports examining the possible causes of hypertransaminasemia in children. The etiology of hypertransaminasemia varied in different studies according to the selected study population. When the etiology is determined, follow-up of the transaminase levels is more confident. But the clinical significance and safe follow-up intervals of incidental hypertransaminasemia with unidentified etiology still are not clear.

In present study, we aimed to determine the underlying etiologies of incidentally determined hypertransaminase in children, and to evaluate the severity and the natural course of transaminase levels.

MATERIAL AND METHODS

We retrospectively reviewed the records of the children for elevated ALT and AST levels who admitted to Turkish Ministry of Health Ankara Child Health and Disease Hematology Oncology Training and Research Hospital pediatric gastroenterology outpatient clinic during January 2010 and January 2013, retrospectively. If AST and/or ALT levels were higher than 40 IU/L, at least twice and persistant for at least 2 months were recruited to the study. Children with incomplete medical records, previously known any chronic diseases including liver and muscle diseases, simultaneous elevated bilirubin levels, whose transaminase levels normalized within a month and who were hospitalized were excluded from the study. Out of the 390 children with hypertransaminasemia, 292 were met the study criteria.

The body mass index (BMI) and relative weight were calculated and interpreted according to the literature. Diagnosis of non-alcoholic fatty liver disease (NAFLD) was based on elevated ALT levels and hepatic steatosis on USG records. The diagnosis of suspected drug-induced liver injury (DILI) (hepatocellular type injury) is defined by ALT > 2 ULN (upper limits of normal) in the patients with history of drug exposure and in whom other possible etiologies were excluded.

The severity of hypertransaminasemia was categorized as mild (< 5 fold of ULN), moderate (between 5 to 10 fold of ULN) and severe (> 10 fold of ULN).

The etiology, severity of hypertransaminasemia, normalization status were re-evaluated for four different age groups as following: <2 years, 2-5 years, >5-12 years, and >12 years.

The Local Clinical Research Ethics Committee of our hospital approved the study (desicion number:2013-147).
Statistical analyses were performed using Statistical Package for Social Science (SPSS) software (ver. 11.0). Results are presented as means ± SDs with descriptive statistics if distribution of variances were normal, median (minimum-maximum) values were given if the distribution of variances weren’t normal. The Student’s unpaired t-test was used as appropriate. When the variances were unequal or the distributions not normal, the Mann-Whitney U-test and X²-test were used as appropriate. The significance level was set at p<0.05.

RESULTS

Demographic characteristics and medical history

Of the 292 patients, 194 (66.4%) were male and 98 (33.6%) were female. The mean age was 6.5±5.4 years old (3 months-18 years) and didn’t differ according to the gender (p>0.05).

At the time of admission, 45.9% of the patients had no complaints. At least one of the following complaints were present in 158 patients; obesity (29.1%), fever (23.4%), abdominal pain (12.7%), vomiting (12.7%), anorexia (6.3%), diarrhea (5.7%), constipation (3.8%), fatigue (2.5%), poor weight gain (2.5%) and abdominal distension (1.3%).

The medical history revealed drug usage in 30 (10.3%) patients. These drugs were antibiotics (50%), antiepileptics (20%), colchium (13.3%), nonsteroid anti-inflammatory drugs (10%), isoniazid (3.3%) and steroid (3.3%). None of patients had a history of herbal consumption and contact with suspicious material that carry the risk of viral hepatitis transmission. Twenty-eight (9.6%) children had an infection history as following; upper respiratory tract infection (71.4%), urinary tract infection (17.9%) and acute otitis media (10.7%).

The family history revealed consanguinity among parents in 36 (12.3%) patients. Liver steatosis (9), chronic Hepatitis B virus (HBV) infection 4, Wilson’s disease 5, muscle disease 5, autoimmune hepatitis 1, cholelithiasis 1 were present in the family members.

Physical examination findings

Of the 292 patients, 222 (76%) had normal physical examination findings. Sixty-one (20.8%) patients had hepatomegaly and 9 (3%) patients had splenomegaly, but none of the patients had icterus, ascites and other chronic liver disease findings.

Among the patients 71 (24.3%) were obese, 16 (5.4%) were overweight and 38 (13%) had wasting.

The etiologic evaluation of hypertransaminasemia

The mean ALT value was 164.9±319.3 IU/L (14–4931 IU/L), and the mean AST value was 156.2±417.3 IU/L (27–6470 IU/L). The males had higher mean AST levels than females (158 ± 493 and 152 ± 197.1 IU/L, respectively) (p =0.015).

The severity of hypertransaminasemia was mild in 238 (81.6%) patients, moderate in 34 (11.6%) patients and severe in 20 (6.8 %) patients.

None of the patients had serologic findings of acute hepatitis A virus (HAV) (0/262), hepatitis C virus (HCV) (0/274), HIV (0/272), toxoplasma (0/219) and rubella infections (0/218). The other infections are shown in Table 1.

Abdominal USG was performed in 278 (95.2%) patients; 137 (49.2%) had normal findings, 108 (38.8%) had hepatomegaly, 80 (28.7%) had hepatic steatosis, 34 (12.2%) had splenomegaly, 16 (5.7%) patients had heterogeneity on liver parenchyma, 6 (2.1%) had gallstones.

Seventeen patients underwent liver biopsy. Chronic active hepatitis (12), micronodular cirrhosis (1), steatohepatitis (1), fibrosis (2), normal liver histopathology (1) were revealed.

None of the patients had elevated serum ferritin level (0/106) and positive sweat chloride test (0/56).

In 191 (65.4%) children the etiology of hypertransaminasemia was identified detected (Table 1). NAFLD was the most common cause of hypertransaminasemia in the study group.

The characteristics of hypertransaminasemia according to etiology was shown in Table 2.

Of the cases diagnosed with NAFLD, 66 (%88) were obese and 2 (2.7%) were overweight. Seven (9.3%) children with NAFLD were in normal weight; 2 of them diagnosed with hereditary fructose intolerance (HFI). According the diagnoses NAFLD patients had the highest mean age (p<0.001). The mean ALT levels was higher than AST levels in patients with NAFLD (p<0.001). Both the mean AST and ALT levels of NAFLD patients were lower than the other diagnoses (p<0.001 and p=0.036 respectively) (Table 2).

The patients diagnosed with infectious diseases were younger than the patients with other specific diagnoses (p=0.02). There was no difference in between the other etiologies in terms of mean age, ALT and AST levels except outlined above (Table 2).
Table 1: The etiology of hypertransaminasemia in the study group

| Etiology                                             | N   | %   |
|------------------------------------------------------|-----|-----|
| Idiopathic                                           | 101 | 34.5|
| Non-alcoholic fatty liver disease                    | 75  | 25.7|
| Infectious diseases                                  | 46  | 15.7|
| - Hepatitis B virus                                  | 13  |     |
| - Cytomegalovirus                                    | 23  |     |
| - Ebstein-Barr virus                                 | 7   |     |
| - Adenovirus                                         | 1   |     |
| - Varicella-zoster virus                             | 1   |     |
| - Brucella                                           | 1   |     |
| Drug induced liver injury                            | 24  | 8.2 |
| - Amoxicillin and clavulanic acid                    | 5   |     |
| - Cephalsporines                                     | 6   |     |
| - *Ampicillin/sulbactam*                             | 2   |     |
| - Isoniazid                                          | 1   |     |
| - Colchicine                                         | 4   |     |
| - Nonsteroid anti-inflammatory drugs                 | 3   |     |
| - Carbamazepine                                      | 1   |     |
| - Valproic acid                                      | 1   |     |
| - Steroids                                           | 1   |     |
| Metabolic/Genetic diseases                           | 15  | 5.1 |
| - Wilson’s disease                                   | 10  |     |
| - Hereditary fructose intolerance                    | 2   |     |
| - Alpha-1 antitrypsin deficiency                     | 2   |     |
| - Pompe disease                                      | 1   |     |
| Elevated creatine kinase levels/Muscle disease       | 16  | 5.4 |
| - Muscular dystrophy                                 | 8   |     |
| Autoimmune hepatitis                                 | 3   | 1.0 |
| Hypothyroidism                                       | 4   | 1.4 |
| Celiac disease                                       | 2   | 0.6 |
| Cholecystitis                                        | 6   | 2.0 |

The characteristics of the patients with an identified etiology and unknown etiology were shown in Table 3. The patients with identified etiology were older (p <0.0001) and had lower mean AST value (p=0.008) than patients with unknown etiology (Table 3).
Table 2: Comparison of age of the patients, severity of hypertransaminasemia and normalization time of transaminases according to the etiologies

|                         | NAFLD (N: 75) | Infectious diseases (N: 46) | DILI (N: 24) | Muscle diseases (N: 16) | Metabolic/Genetic diseases (N: 15) |
|------------------------|---------------|----------------------------|--------------|------------------------|-----------------------------------|
| Age (months)           | 133.9±42.1    | 57±64                      | 87.6±64.5    | 82.7±58.7              | 80.1±51.2                         |
| (mean±SD)              |               |                            |              |                        |                                   |
| AST (IU/l)             | 63.9±35.1     | 148±134.8                  | 127±122      | 247±180.3              | 142±99.5                          |
| (mean±SD)              |               |                            |              |                        |                                   |
| ALT (IU/l)             | 103.4±62.1    | 163.3±152.8                | 144±150      | 203.5±101.4            | 174±130.5                         |
| (mean±SD)              |               |                            |              |                        |                                   |
| Mild hypertransaminasemia (N, %) | 72 (94.6) | 32 (69.6)                  | 20 (83.3)    | 12 (75)                | 9 (60)                            |
| Mean normalization time (months) | 5.9±4.6 | 5.8±4.4                    | 2.7±1.1      | -                      | 7.4±3.9                           |

NAFLD: Non-alcoholic fatty liver disease, DILI: Drug induced liver injury, AST: Aspartate aminotransferase, ALT: Alanine aminotransferase

Table 3: The comparison of the patients with and without certain etiology

|                         | Identified etiology (N: 191) | Unidentified etiology (N: 101) | P value |
|------------------------|-------------------------------|--------------------------------|---------|
| Age (months) (mean±SD) | 97±62                         | 47.5±57                         | <0.0001 |
| ALT (IU/l) (mean±SD)   | 139.8±125                     | 202.2±489                      | N.S.    |
| AST (IU/l) (mean±SD)   | 117.2±113                     | 219.5±65.5                     | 0.008   |
| Normalization time (months) | 5.3±4.1                    | 5.1±5.1                        | N.S.    |

ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, N.S.: Non significant

Course of the transaminase levels

The transaminase levels were normalized in 118 (40.4%) patients at mean 5.3 ± 4.4 (range: 2-21) months, of them 86 (72.8%) achieved normalization in less than 6 months.

The patients who had normalization of transaminases were older than others (mean age 88±65.9 months vs 71.7±64.3 months, respectively (p=0.03).

There were no significant difference in normalization status and normalization period according to the severity of hypertransaminasemia and gender (p>0.05).

Normalization of transaminases were determined in 82 (45.5%) patients with known etiology and 36 (32.2%) patients with unknown etiology. The normalization period of the patients with or without a known etiologic factor were similar to each other (Table 3).

The normalization status did not differ according to the etiological factors, except the patients with DILI who had an shortest normalization time (2.7±1.1 months) than all other diagnoses (p=0.015) (Table 2).

The most common diagnoses in the patients who had elevated transaminases for 6 months or more were NAFLD and genetic/metabolic disorders.

Hypertransaminasemia according to age groups

The comparison of age groups in terms of mean ALT and AST values, etiology, normalization status and normalization time were presented in Table 4.

One hundred twenty-six (66%) of the patients with known etiology were older than 5 years old and the 75% of the patients with unknown etiology were younger than 5 years old.

The mean AST levels of patients younger than 5
years-old were significantly higher than patients older than 5 years-old (p<0.001) (Table 4). Twenty-four (52.1%) patients diagnosed with infectious diseases were younger than 2 years-old. Seventy-one patients with NAFLD (94.6%) were older than 5 years-old (Table 3).

Table 4: The comparison of age groups in terms of mean ALT and AST values, normalization status and etiologies

| Age groups          | <2 years old (N=99) | 2-5 years old (N=44) | 5-12 years old (N=91) | >12 years old (N=58) |
|---------------------|---------------------|----------------------|-----------------------|---------------------|
| ALT (IU/l) (mean±SD)| 187.6±498.3         | 256.2±268.1          | 127.3±112.7           | 116.3±86.8          |
| AST (IU/l) (mean±SD)| 200.5±646.7         | 250.2±377.8          | 113±155.4             | 76.8±70.2           |
| Normalization of transaminases | 33 (33.3%) | 17 (38.6%) | 38 (41.8%) | 30 (51.7%) |
| Certain etiology (N: 191) | 42 (22%) | 23 (12%) | 76 (39.8%) | 50 (26.2%) |
| NAFLD (N: 75) | 3 (4%) | 1 (1.3%) | 41 (54.6%) | 30 (40%) |
| Infectious diseases (N: 46) | 24 (52.2%) | 9 (19.6%) | 10 (21.7%) | 7 (15.2%) |
| DILI (N: 24) | 5 (20.8%) | 5 (20.8%) | 9 (37.5%) | 5 (20.8%) |
| Metabolic/Genetic diseases (N: 15) | 3 (20%) | 2 (13.3%) | 8 (53.3%) | 2 (13.3%) |
| AIH (N: 3) | - | - | 3 (100%) | - |
| Others (N: 28) | 7 (25%) | 10 (35.7%) | 5 (17.9%) | 6 (21.4%) |

ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, NAFLD: Non-alcoholic fatty liver disease, DILI: Drug induced liver injury, AIH: Autoimmune hepatitis

DISCUSSION

In previous studies, the prevalence of the conditions related to hypertransaminasemia differed due to the study population. Whether some of them included HAV infections, some of them excluded obesity, hepatotropic virus infections or drug usage. They reported that most common causes of elevated transaminases were infections (31.2%-34%) and obesity related NAFLD (17.6%-11.1%). We determined NAFLD (25.7%) and infectious diseases (15.7%) were the common causes. Despite HAV infection is the leading infectious causes of acute hepatitis in our country, due to its cholestatic pattern, there wasn’t any patient in our study. So the prevalence of infectious disease was found as the second frequent cause of hypertransaminasemia or may be the result of increased childhood obesity rates in recent years. NAFLD is frequently associated with childhood obesity. The prevalence of fatty liver disease in obese children has been reported to be between 10% and 77% in 14-19. In our study, 66 (93%) of 71 obese children had NAFLD. It was shown that the frequency of NAFLD increased with age; such as NAFLD reported to be in 0.7% between age of 2-4 years and in 17.3% between age of 12-15 years 19. Similarly, we showed that NAFLD increased with age, only 5.3% of NAFLD patients were younger than 5 years old and 51.7% of them older than 12 years old. Also similar to the previous studies, we found mildly elevated ALT levels, and elevation of ALT is higher than AST 20,21.

The frequency of NAFLD in normal weight children was reported as 5-20% and metabolic diseases should be considered 21. We demonstrated 2 children with NAFLD within normal weight had hereditary fructose intolerance.

The most common causes of viral hepatitis are hepatotropic virus infections (90%) and the remaining ones are due to non-hepatotropic virus infections like Cytomegalovirus (CMV) and Epstein–Barr virus (EBV). Ioro et al.(5) reported that the viral infections (31.2%) were the most common causes of hypertransaminasemia, despite excluding of the hepatotropic viruses from the study. EBV (62.4%) and CMV (31.5%) were the most common non-hepatotropic virus infections in their study (5). In our study, the most common viral agents were CMV (50%), HBV (28.2%) and EBV (15.2%). We thought that this difference of our findings from the literature may be due to vaccination programs for HBV in our country and exclusion of HAV infections.
Many drugs may alter liver functions and liver toxicity may be seen in various forms; ranging from mild transaminase elevation to fulminant hepatitis. The DILI was reported as a cause of elevated transaminases (18.1%-3%) in different studies. Our diagnosis of DILI was 8.2% and mostly related to antibiotic usage. It may be a result of higher rates of antibiotic usage in our country. Similar to the previous studies, amoxicillin-clavulanic acid was the one of the most common associated antibiotic with DILI. Also the mean normalization time of patients with DILI was the most shorter period compared to others.

Most of the genetic/metabolic diseases alter liver functions. Iorio et al. found that genetic metabolic disorders were responsible about 12% of hypertransaminasemia and most common diagnoses were Wilson’s disease (4.2%) in our study. The frequency of genetic/metabolic disorders was 5.1%. The most frequent metabolic/genetic disease was Wilson’s disease (3.4%). Also rare genetic/metabolic disease as hereditary fructose intolerance and Pompe disease were diagnosed in appropriate tests. The low rate of our metabolic disease may be due to excluding cholestatic patients, age range and limited genetic tests.

Liver enzyme abnormalities are common in thyroid diseases. Hypothyroidism cause a mild to moderate increase in transaminase levels. In our study, we detected hypothyroidism in 1.4% of the cases. Transaminase elevation was mild to moderate and on follow-up, under hormone replacement treatment, transaminases were normalized.

Autoimmune hepatitis (AIH) may be presented with asymptomatic hypertransaminasemia but early diagnosis and treatment should be made due to the potential of rapid progression, even in fulminant liver failure. In several studies, AIH was responsible for 1.6-2.5% of hypertransaminasemia. In our study, 1% of the children diagnosed with AIH and transaminases were normalized with treatment in all cases.

Liver enzymes may be elevated due to muscle disorders. Because of the accessibility of CK level measurement, it should be evaluated in the first step examination of hypertransaminasemia. Ioro et al. reported, 3.2% of children with hypertransaminasemia had muscular dystrophy. In our study, hypertransaminasemia was related with muscle disease involvement in 5.4% of children, of them 2.7% had muscular dystrophy.

Celiac disease is a common inflammatory enteropathy in genetic predisposing patients and may be presented in various forms. Asymptomatic patients may be presented with asymptomatic hypertransaminasemia incidentally. We determined 0.6% of patients had celiac disease without any symptoms.

The etiology of transaminase elevation may not always be identified. In the study by Çeltik et al., which included only hospitalized patients, the idiopathic rate was found to be 27.1%. In another study from Turkey, the causes could not be determined in 18 (6.4%) of the patients. We could not identify the etiology in 109 (37.3%) patients, despite appropriate laboratory, genetic tests and histopathological evaluation.

We studied whether the severity of hypertransaminase levels vary according to the underlying disease. We determined that patients with toxic hepatitis and acute viral hepatitis had more severe hypertransaminasemia and patients with the NAFLD had more mild hypertransaminasemia.

In our study, the normalization rate was 40.4% in mean 5.3±4.4 months. We found that the rate of normalization in diagnosed cases (45.5%) was significantly higher than those undiagnosed (32.2%), which may be related to the treatment and natural course of self-limiting infections. Transaminase normalization did not correlate with gender, grade of transaminase elevation and age groups. In children with persistent hypertransaminases longer than 6 months, most common diagnoses were NAFLD and genetic conditions. Similarly, we found NAFLD was common in patients who had hypertransaminasemia longer than 6 months.

The limitations of our study are as following: being a retrospective study, only patients who admitted to our outpatient clinic, not studying macro-AST, and lost of the patients on follow-up, not study macro-AST.

CONCLUSION

Many liver and non-liver diseases cause transaminase elevation in children. The NAFLD and infections were the most common diagnoses. The severity of hypertransaminasemia, age group of the patients, a careful medical and family history may lead the correct stepwise approach to diagnose. The patients who are undiagnosed should be follow-up for normalization of transaminases and further diagnostic tests like whole exome sequence analysing should be planned according to the course of transaminases.

REFERENCES

1. Vajro PM, Maddoluno S, Veropalumbo C. Persistent hypertransaminasemia in asymptomatic
children: A stepwise approach. World J Gastroenterol 2013; 14; 19: 2740–2751.

2. Rook M, Rosenthal P. Caring for adults with pediatric liver disease. Curr Gastroenterol Rep 2009; 11: 83-89 [PMID: 19166664 DOI: 10.1007/s11894-009-0013-7]

3. Hyun HJ, Shim JJ, Kim JW, Lee JS, Lee CK, Jang JY, et al. The prevalence of elevated alanine transaminase and its possible causes in the general Korean population. J Clin Gastroenterol 2014; 48(6):534-539. doi: 10.1097/MCG.0b013e3182a474d3

4. Çeltik C, Erbaş H, Kurşun ÖS, Bostancıoğlu M, İnan M, Öner N et al. The Reasons of Elevated Serum Transaminases in Childhood [Article in Turkish]. Turk J Biochem 2008; 33(4):175–181.

5. Iorio R, Sepe A, Giannattasio A, Cirillo F, Vegnente A. Hypertransaminasemia in childhood as a marker of genetic liver disorders. J Gastroenterol 2005; 40: 820-826.

6. Serdaroglu F, Koca T, Dereci S, Akcam M. The etiology of hypertransaminasemia in Turkish children.. Bosn J Basic Med Sci. 2016;16(2):151-156.

7. Strauss RS, Barlow SE, Dietz WH. Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents. J Pediatr. 2000;136:727–733

8. Ahmar Shamim, Nimain C, Mohanty. Etiological Spectrum of Children Presenting With Raised Liver Transaminases and Their Outcome in a Tertiary Care Pediatric Facility at Navi Mumbai, India. Clinical Gastroenterology and Hepatology 2015; Vol. 13, No. 7.

9. Krebs NF, Himes JH, Jacobson D, Nicklas TA, Guilday P, et al. (2007) Assessment of child and adolescent overweight and obesity. Pediatrics 120: S193–S228.

10. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH (2000) Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 320: 1240–1243.

11. Fishbein MH, Miner M, Mogren C, Chalekson J. The spectrum of fatty liver in obese children and the relationship of serum aminotransferases to severity of steatosis. J Pediatr Gastroenterol Nutr 2003; 36(1):54–61. http://dx.doi.org/10.1097/0005176-200301000-00012.

12. Tajiri K, Shimizu Y. Practical guidelines for diagnosis and early management of drug-induced liver injury. World J Gastroenterol 2008; 14(44):6774-6785. http://dx.doi.org/10.3748/wjg.14.6774

13. Gilbert-Barnes E, Barness LA, Farrell PM. Clinical Use of Pediatric Diagnostic Tests. 6th ed. Philadelphia. Lippincott Williams, Wilkins. 2003; 20-56.

14. Schwimmer JB, Deutsch R, Kahan T, Lavine JE, Stanley C. Prevalence of fatty liver in children and adolescents. Pediatr 2006; 118: 1388-1393.

15. Franzese A, Vajro P, Argenziano A, Rubino A, Brunetti F, Saviano MC, et al. Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci. 1997;42:1428 – 1432

16. Tazawa Y, Noguchi H, Nishinomiya F, Takada G. Serum alanine aminotransferase activity in obese children. Acta Peditr. 1997;86:238 –241

17. Purcell M, Flores YN, Zhang ZF, Denova-Gutiérrez E, Salmeron J. Prevalence and predictors of alanine aminotransferase elevation among normal weight, overweight and obese youth in Mexico. J Dig Dis 2013; 14(9):491-499. http://dx.doi.org/10.1111/1751-2980.12072.

18. Larrey D. Drug induced liver disease. J Hepatol 2000; 32: 77-78.
24. Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug induced liver disease. Hepatol 2005; 42: 481-489.

25. Pandit A, Sachdeva T, Bafna P. Drug-Induced Hepatotoxicity: A Review. JAPS 2012; 02: 233-243.

26. Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008;135:1924-1934. 1934 e1921-1924.

27. Burra P, Lecturer S. Liver abnormalities and endocrine diseases. Clin Gastroenterol 2013; 27: 553-563.

28. García Romero R, Martín de Carpi J, Bernal Cuartas C, Pinillos Pisón S, Varea Calderón V. Autoimmune hepatitis in pediatric patients. Rev Esp Enferm Dig 2007; 99 255-258.

29. Clark J, Brancati F, Diehl A. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003; 98: 960-967.